Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
Public ClinicalTrials.gov record NCT03289273. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma
Study identification
- NCT ID
- NCT03289273
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 1,010 participants
Conditions and interventions
Conditions
Interventions
- Regorafenib (Stivarga, BAY73-4506) Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 12, 2017
- Primary completion
- Jan 30, 2022
- Completion
- Jun 20, 2022
- Last update posted
- Jun 12, 2023
2017 – 2022
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| St. Joseph´s Hospital and Medical Center | Phoenix | Arizona | 85013 | — |
| University of Florida Health | Gainesville | Florida | 32610 | — |
| University of Louisville - Clinical Trials Unit | Louisville | Kentucky | 40202 | — |
| University Medical Center | New Orleans | Louisiana | 70112 | — |
| Mercy Medical Center | Baltimore | Maryland | 21202 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Rutgers University | Newark | New Jersey | 07101-1709 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| C.R.Wood Cancer Center, Glen Falls Hospital | Glens Falls | New York | 12801 | — |
| University of Cincinatti | Cincinnati | Ohio | 45267 | — |
| Corporal Michael J. Crescenz VA Medical Center | Philadelphia | Pennsylvania | 19104 | — |
| Einstein Medical Center | Philadelphia | Pennsylvania | 19141 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03289273, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 12, 2023 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03289273 live on ClinicalTrials.gov.